Cargando…
New therapeutic approaches for Krabbe disease: The potential of pharmacological chaperones
Missense mutations in the lysosomal hydrolase β‐galactocerebrosidase (GALC) account for at least 40% of known cases of Krabbe disease (KD). Most of these missense mutations are predicted to disrupt the fold of the enzyme, preventing GALC in sufficient amounts from reaching its site of action in the...
Autores principales: | Spratley, Samantha J., Deane, Janet E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5031207/ https://www.ncbi.nlm.nih.gov/pubmed/27638604 http://dx.doi.org/10.1002/jnr.23762 |
Ejemplares similares
-
Azasugar inhibitors as pharmacological chaperones for Krabbe disease
por: Hill, Chris H., et al.
Publicado: (2015) -
Molecular Mechanisms of Disease Pathogenesis Differ in Krabbe Disease Variants
por: Spratley, Samantha J., et al.
Publicado: (2016) -
Hematopoietic Stem cell transplantation and lentiviral vector‐based gene therapy for Krabbe's disease: Present convictions and future prospects
por: Hu, Peirong, et al.
Publicado: (2016) -
Krabbe disease: New hope for an old disease
por: Bradbury, Allison M., et al.
Publicado: (2021) -
Neuroimmune mechanisms in Krabbe's disease
por: Potter, Gregory B., et al.
Publicado: (2016)